
    
      Individually randomized, open label, 2-arm, cross-over, clinical trial. Patients are
      allocated to receive rectal artesunate at admission and intravenous artesunate after 12 hours
      or intravenous artesunate at admission and rectal artesunate after 12 hours. All patients are
      treated for severe malaria with intravenous quinine. Frequent blood samples are taken at
      fixed intervals after the administration of the first and the second dose of study drug. The
      time frame is 24 hours and thereafter patients continue the standard antimalarial therapy.
    
  